ArticleNeuropsychiatric disease and treatment2012
Optimal treatment of social phobia: systematic review and meta-analysis.
Article in Neuropsychiatric disease and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Brazilian Psychiatric Association guidelines for the treatment of social anxiety disorder.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Guideline
- Bibliometric analysis of trends, innovations, and the future of CBT-based mobile interventions for depression.Frontiers in medicine · 2025Pooled it
- Interpersonal neural synchrony and mental disorders: unlocking potential pathways for clinical interventions.Frontiers in neuroscience · 2024Pooled it
- Candidate Biological Markers for Social Anxiety Disorder: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review.Current psychiatry reports · 2016Pooled it
- Trial
- Impact of cognitive-behavioral therapy for social anxiety disorder on the neural bases of emotional reactivity to and regulation of social evaluation.Behaviour research and therapy · 2014Trial
- Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.Scientific reports · 2023Article
- Article
- Diet and Anxiety: A Scoping Review.Nutrients · 2021Article
- Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.Neurology international · 2021Review
- Commentary: Gray Matter Structural Alterations in Social Anxiety Disorder: A Voxel-Based Meta-Analysis.Frontiers in psychiatry · 2019Article
- Avoidant personality disorder: current insights.Psychology research and behavior management · 2018Review
- Group cognitive behavioral therapy modulates the resting-state functional connectivity of amygdala-related network in patients with generalized social anxiety disorder.BMC psychiatry · 2016Article
- Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders.The Psychiatric quarterly · 2016Article
- The Cost Effectiveness of Psychological and Pharmacological Interventions for Social Anxiety Disorder: A Model-Based Economic Analysis.PloS one · 2015Article
- Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan.Drugs - real world outcomes · 2014Article
- Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.BMC psychiatry · 2014Review
- Reliability, validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with social phobia.Health and quality of life outcomes · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article proposes a number of recommendations for the treatment of generalized social phobia, based on a systematic literature review and meta-analysis. An optimal treatment regimen would include a combination of medication and psychotherapy, along with an assertive clinical management program. For medications, selective serotonin reuptake inhibitors and dual serotonin-norepinephrine reuptake inhibitors are first-line choices based on their efficacy and tolerability profiles. The nonselective monoamine oxidase inhibitor, phenelzine, may be more potent than these two drug classes, but because of its food and drug interaction liabilities, its use should be restricted to patients not responding to selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. There are other medication classes with demonstrated efficacy in social phobia (benzodiazepines, antipsychotics, alpha-2-delta ligands), but due to limited published clinical trial data and the potential for dependence and withdrawal issues with benzodiazepines, it is unclear how best to incorporate these drugs into treatment regimens. There are very few clinical trials on the use of combined medications. Cognitive behavior therapy appears to be more effective than other evidence-based psychological techniques, and its effects appear to be more enduring than those of pharmacotherapy. There is some evidence, albeit limited to certain drug classes, that the combination of medication and cognitive behavior therapy may be more effective than either strategy used alone. Generalized social phobia is a chronic disorder, and many patients will require long-term support and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.